Autoimmunity, spontaneous tumouringenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1

Journal of Pathology

Volumn 211, Issue 5, 2007, Pages 591-601

  Ivanova, Alla V ^a,d   Ivanov, S V ^a,d   Pascal, V ^a   Lumsden, J M ^b   Ward, J M ^c   Morris, N ^a   Tessarolo, L ^a   Anderson, S K ^a   Lerman, M I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SOBRAN INC   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Fus1 knockout; IL 15; Tumour suppressor

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 15; PROTEIN FUS1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN PRECURSOR; TUMOR PROTEIN; UBIQUITIN; UBIQUITIN PRECURSOR;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARCINOGENESIS; CELL MATURATION; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; GENE DISRUPTION; GLOMERULONEPHRITIS; HYPOTHESIS; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNOREGULATION; INNATE IMMUNITY; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC VASCULITIS; TUMOR IMMUNITY; VASCULAR TUMOR; ANGIOSARCOMA; ANIMAL; GENETICS; HEMANGIOMA; IMMUNOLOGY; MITOCHONDRION; NEOPLASM; PHENOTYPE; PHYSIOLOGY; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE; VASCULITIS;

ANIMALS; AUTOIMMUNITY; GENES, TUMOR SUPPRESSOR; HEMANGIOMA; HEMANGIOSARCOMA; IMMUNITY, NATURAL; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MITOCHONDRIA; NEOPLASM PROTEINS; NEOPLASMS; PHENOTYPE; PROTEIN PRECURSORS; RNA, MESSENGER; TISSUE DISTRIBUTION; UBIQUITINS; VASCULITIS;

EID: 33947663485     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2146     Document Type: Article

References (51)

1. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-6133.
2. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y, et al. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 2001;20:6258-6262.
3. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733-739.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
6. Dunn GP, Old U, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
7. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004;22:405-429.
8. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-463.
9. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki EE, et al. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 2005;174:1213-1221.
10. Lodolce JP, Boone DL, Chai S, Swain RE, Themistocles D, Trettin S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-676.
11. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-780.
12. Bonin A, Reid SW, Tessarollo L. Isolation, microinjection, and transfer of mouse blastocysts. Methods Mol Biol 2001;158:121-134.
13. Tessarollo L. Manipulating mouse embryonic stem cells. Methods Mol Biol 2001;158:47-63.
14. Ivanov SV, Ward JM, Tessarollo L. Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol 2004;165:1007-1018.
15. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN, et al. Myristoylation of the Fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 2004;64:2969-2976.
16. Haines DC, Chattopadhyay S, Ward JM. Pathology of aging B6;129 mice. Toxicol Pathol 2001;29:653-661.
17. Ramdial PK, Chetty R. Vasculitis-induced membranous fat necrosis. J Cutan Pathol. 1999;26:405-410.
18. Ng PP, Tan SH, Tan T. Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 2002;41:488-490.
19. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501-537.
20. Sco P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39-50.
21. Bjornsson J. Histopathology of primary vasculitic disorders. In Inflammatory Diseases of Blood Vessels, Hoffman GS, Weyand CM (eds). Marcel Dekker: New York, 2002; 255-265.
22. Dorfman JR, Raulet RH. Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med 1998;187:609-618.
23. Williams NS, Kubota A, Bennett M, Kumar V, Takei F. Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur J Immunol 2000;30:2074-2082.
24. Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 2002;3:523-528.
25. Makrigiannis AP, Anderson SK. Regulation of natural killer cell function. Cancer Biol Ther 2003;2:610-616.
26. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a killer? Nat Rev Immunol 2003;3:413-425.
27. Sivakumar PV, Williams NS, Puzanov IJ, Schatzle JD, Bennett M, Kumar V. Development of self-recognition systems in natural killer cells. Adv Exp Med Biol 1998;452:1-12.
28. Perera LP. Interleukin 15: its role in inflammation and immunity. Arch Immunol Ther Exp (Warsz) 2000;48:457-464.
29. Ohteki T, Suzue K, Maki C, Ota T, Koyasu S. Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Inummol 2001;2:1138-1143.
30. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-124.
31. Williams NS, Klem J, Puzanov IJ. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev 1998;165:47-61.
32. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001;97:14-22.
33. Liu CC, Perussia B, Young JD. The emerging role of IL-15 in NK-cell development. Immunol Today 2000;21:113-116.
34. Schluns KS, Nowak EC, Cabrera-Hernandez A, Puddington L, Lefrancois L, Aguila HL. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression. Proc Natl Acad Sci USA 2004;101:5616-5621.
35. Ogasawara K, Hida S, Azimi N. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-703.
36. + T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med 1998; 187:967-972.
37. Wilder JA, Koh CY, Yuan D. The role of NK cells during in vivo antigen-specific antibody responses. J Immunol 1996;156:146-152.
38. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97:2731-2736.
39. Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1993;2:227-231.
40. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity 2002;35:1-14.
41. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-474.
42. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 2004;14:277-287.
43. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248:171-183.
44. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside, PS, Doetschman T. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999;59:337933-337986.
45. Engle SJ, Ormsby I, Pawlowski S. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002;62:6362-6366.
46. Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases-a descriptive epidemiological study. Rheumatol Int 2002;22:233-237.
47. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003;90:103-122.
48. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
49. Knudson AG. Anti-oncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-10921.
50. Zhang L, Pagano JS. Structure and function of IRF-7. J Interferon Cytokine Res 2002;22:95-101.
51. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005;122:669-682.